Related Experiment Video
Updated: Oct 9, 2025
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
Exploring the Value of BRD9 as a Biomarker, Therapeutic Target and Co-Target in Prostate Cancer
Nafisa Barma1, Timothy C Stone1, Lina Maria Carmona Echeverria1,2
1Division of Surgery and Interventional Sciences, University College London, London WC1E 6BT, UK.
Background And Aims:
Despite recent advances in advanced prostate cancer treatments, clinical biomarkers or treatments for men with such cancers are imperfect. Targeted therapies have shown promise, but there remain fewer actionable targets in prostate cancer than in other cancers. This work aims to characterise BRD9, currently understudied in prostate cancer, and investigate its co-expression with other genes to assess its potential as a biomarker and therapeutic target in human prostate cancer.
Materials And Methods:
Omics data from a total of 2053 prostate cancer patients across 11 independent datasets were accessed via Cancertool and cBioPortal. mRNA M.expression and co-expression, mutations, amplifications, and deletions were assessed with respect to key clinical parameters including survival, Gleason grade, stage, progression, and treatment. Network and pathway analysis was carried out using Genemania, and heatmaps were constructed using Morpheus.
Results:
BRD9 is overexpressed in prostate cancer patients, especially those with metastatic disease. BRD9 expression did not differ in patients treated with second generation antiandrogens versus those who were not. BRD9 is co-expressed with many genes in the SWI/SNF and BET complexes, as well as those in common signalling pathways in prostate cancer.
Summary And Conclusions:
BRD9 has potential as a diagnostic and prognostic biomarker in prostate cancer. BRD9 also shows promise as a therapeutic target, particularly in advanced prostate cancer, and as a co-target alongside other genes in the SWI/SNF and BET complexes, and those in common prostate cancer signalling pathways. These promising results highlight the need for wider experimental inhibition and co-targeted inhibition of BRD9 in vitro and in vivo, to build on the limited inhibition data available.
Insights
BRD9 is overexpressed in prostate cancer, particularly metastatic disease, showing potential as a diagnostic and therapeutic target. Further research into BRD9 inhibition is warranted for advanced prostate cancer treatments.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Advanced prostate cancer treatments and biomarkers remain imperfect.
- Fewer actionable therapeutic targets exist in prostate cancer compared to other cancers.
- BRD9 is an understudied gene in the context of prostate cancer.
Purpose of the Study:
- To characterize BRD9 expression in prostate cancer.
- To investigate BRD9 co-expression with other genes.
- To assess BRD9's potential as a biomarker and therapeutic target.
Main Methods:
- Analyzed omics data from 2053 prostate cancer patients across 11 datasets.
- Assessed mRNA expression, co-expression, mutations, amplifications, and deletions.
- Utilized network and pathway analysis (Genemania) and heatmaps (Morpheus).
Main Results:
- BRD9 is overexpressed in prostate cancer, especially in metastatic cases.
- BRD9 expression did not significantly differ based on second-generation antiandrogen treatment.
- BRD9 co-expressed with SWI/SNF, BET complex genes, and prostate cancer signaling pathways.
Conclusions:
- BRD9 shows potential as a diagnostic and prognostic biomarker for prostate cancer.
- BRD9 is a promising therapeutic target, especially for advanced prostate cancer.
- BRD9 may serve as a co-target with genes in SWI/SNF, BET complexes, and signaling pathways, requiring further in vitro and in vivo studies.
